A multicenter study evaluating outcomes of lymphoma patients approved for licenced CD19 CAR-T who were deemed unfit for autologous stem cell transplant
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 03 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association